XFOR Archives - BioTuesdays

Markets

Cantor starts X4 Pharma at OW; PT $3

Cantor Fitzgerald launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with an “overweight” rating and a 12-month price target of $3. The stock closed at 80 cents on Dec. 22. X4 is a clinical-stage biopharmaceutical...

December 22, 2022

Markets

Brookline starts X4 Pharma at buy; PT $21

Brookline Capital Markets launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $21 price target. The stock closed at $6.10 on Dec. 16. X4 Pharmaceuticals is focused on diseases resulting from...

December 17, 2020

Developments

X4 Pharma’s mavorixafor gets FDA fast track designation for WHIM syndrome

The FDA granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor fast track designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and myelokathexis, or low white...

October 8, 2020

Developments

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

X4 Pharmaceuticals (NASDAQ:XFOR) reported positive results from its ongoing Phase 2 trial of mavorixafor for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

June 12, 2020

Developments

X4 Pharma starts Phase 1b trial of mavorixafor for Waldenström’s macroglobulinemia

X4 Pharmaceuticals (NASDAQ:XFOR) initiated a Phase 1b trial of mavorixafor in combination with ibrutinib, a Burton tyrosine kinase (BTK) inhibitor, for the treatment of Waldenström’s macroglobulinemia (WM). WM is a rare...

December 30, 2019

Markets

Roth starts X4 Pharma at buy; PT $20

Roth Capital Partners launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $20 price target. The stock closed at $11 on Dec. 17. Analyst Zegbeh Jallah writes that her investment thesis is based...

December 18, 2019

Developments

X4 Pharma’s mavorixafor gets FDA breakthrough therapy designation for WHIM syndrome

The FDA granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor breakthrough therapy designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and myelokathexis, or...

November 12, 2019

Developments

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

The European Commission (EC) granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor orphan drug designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

August 1, 2019

Tag - XFOR

Cantor starts X4 Pharma at OW; PT $3

Brookline starts X4 Pharma at buy; PT $21

X4 Pharma’s mavorixafor gets FDA fast track designation for WHIM syndrome

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

X4 Pharma starts Phase 1b trial of mavorixafor for Waldenström’s macroglobulinemia

Roth starts X4 Pharma at buy; PT $20

X4 Pharma’s mavorixafor gets FDA breakthrough therapy designation for WHIM syndrome

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

General

More